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Abstract 
Thalassaemia is a common autosomal recessive disorder and have a high 
incidence among people of Asian Indian origin, Southeast Asian and Northern 
Thailand. It is classified into a-thalassaemia and 13-thalassaemia. Thalassaemia is 
due to quantitative reductions in globin chains synthesis. Thalassaemia 
haemoglobinopathies are structural abnormalities of haemoglobin synthesis, 
where the synthesis of these haemoglobins are reduced in amount. 
To data, there is limited study on the effect of blood donation from a thalassaemia 
donor. So objectives of this study were to determine the prevalence and the type 
of thalassaemia among blood donors in Hospital Universiti Sains Malaysia 
(HUSM); and to use the data for future protocol in blood transfusion therapy. A 
total of 80 blood samples were obtained from the donors at the Transfusion 
Medical Unit, HUSM. 91.3% of donors were Malays, 1.3% was Chinese and 1.0% 
was Indian. 
The donors were selected according to the standard criteria. Thalassaemia 
screening was carried out using haemoglobin electrophoresis method. Hb A2 
elution technique and quantitation of Hb F were performed. Most of the blood 
donors, 15% (n = 12) were diagnosed as thalassaemia 1 haemoglobinopathy. Out 
of that, 1 0 donors presented as microcytic hypochromic and 2 donors were 
normocytic normochromic. 
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The type of thalassaemia were Hb E/ a-thalassaemia in 5 donors, Hb E trait in 3 
donors, J3-thalassaemia in 3 donors and Hb E IJ3-thalassaemia in 1 donor. This 
findings were consistent to previous study or population study done by Vella 
(1962); Lie-injo & Duraisamy (1972); Ganesan et al (1976); showing that Hb E 
haemoglobinopathy is prevalence among Kelantan population. 
Screening test for thalassaemia trait is suggested to be included as the standard 
procedure of blood test before blood donation especially for the apheresis 
procedures. Further research is required to investigate the hypothesis that RBC 
from a donor with the thalassaemia will interfere with the purity of the platelet 
apheresis product. 
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Chapter 1 
Introduction 
In Malaysia, there is a need to raise public awareness of thalassaemia. With 
public education, screening for thalassaemia becomes feasible. In addition every 
medical practitioner should look for evidence of thalassaemia from a full blood 
count. If the mean corpuscular volume (MCV) is low, it should be investigated for 
iron deficient erythropoiesis or thalassaemia (George et. al 1994). 
1.1 Thalassaemias 
These are a heterogeneous group of genetic disorders, which result from a 
reduced rate of synthesis of a or J3 chains. Clinically they are divided into hydrops 
foetalis, J3-thalassaemia major, which is transfusion dependent, thalassaemia 
intermedia characterized by moderate anaemia usually with splenomegaly and 
iron overload, and thalassaemia minor, the usually symptomless carrier 
( A.V.Hoffbrand & J.E.Pettit 1993). 
3 
1.1.1 Thalassaemia: Epidemiology 
Thalassaemia is an inherited disease of haemoglobin synthesis. It is a public 
health problem in Malaysia. About 4.5% of people in Malaysia are heterozygous 
carries for 13- thalassaemia and couples that are carries are at risk of producing a 
child with 13- thalassaemia major. In Malays ian-Chinese, 4.5% are carries of the a-
thal-1 or a0 -thalassaemia gene. The Malaysian-Chinese couples that are carries 
of the a0 -thalassaemia gene are risk of having a fetus with Hb Bart's hydrops 
fetalis (Elizabeth George 1998). 
The thalassemias are a diverse group of genetic blood diseases characterized by 
absent or decreased production of normal hemoglobin, resulting in a microcytic 
anaemia of varying degree. The a-thalassaemias are concentrated in Southeast 
Asia, Malaysia and Southern China (Fucharoen S, Winichagoon P. 1992). 
The f3-thalassaemias are seen primarily in the areas surrounding Mediterranean 
Sea, Africa and Southeast Asia. Due to global migration patterns, there has been 
an increase in the incidence of thalassaemia in North America in the last ten 
years; primarily due to immigration from Southeast Asia. The genetic defect of 
hemoglobin are the most common genetic disorders worldwide. They occur in 
tropical and sub tropical areas (Figure 1.0). 
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Figure 1.0: The geographical distribution of the thalassaemia and the more 
common, inherited structural haemoglobin abnormalities ( A.V.Hoffbrand & 
J.E.Pettit 1993). 
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1.2 Normal Haemoglobin Structure 
In the normal adult, Haemoglobin A, which is composed of two alpha and two beta 
globins (a2J32), is the most prevalent, comprising about 95°/0 of all haemoglobin. 
Two minor haemoglobins also occur, Haemoglobin A2, composed of two alpha 
and two delta globins (a2o2) comprises 2-3.5°k of haemoglobin, while haemoglobin 
F, composed of two alpha and two gamma globins ( a2y2), comprises less than 2% 
of haemoglobin. 
Haemoglobin F, or fetal haemoglobin, is produced by the fetus in uterus and until 
about 48 weeks after birth. Haemoglobin F has a high oxygen-affinity in order to 
attract oxygen from maternal blood and deliver it to the fetus. After birth, the 
production of adult haemoglobin rapidly increases and fetal haemoglobin 
production drops off. 
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Figure 1.1: Globin Chain production and development. 
The alpha globin, molecule concentration is rather stable in fetal and adult life, 
because it is needed for both fetal and adult haemoglobin production. The beta 
globin appears early in fetal life at low levels and begins to rapidly increase after 
30 weeks gestational age, reaching a maximum about 30 weeks postnatal. The 
gamma globin molecule reaches a high level early in fetal life at about 6 weeks 
and begins to decline about 30 weeks gestational age, reaching a low level about 
48 weeks post gestational age. The delta globin appears at a low level at about 30 
weeks gestational age and maintains a low profile throughout life (Figure 1.1) 
(Robert S. Hillman, Kenneth A . Ault 1995). 
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1.3 Pathogenesis of Thalassaemia 
In the thalassaemia patient, a mutation or deletion of the genes that control globin 
production will lead to a decrease production of the corresponding globin chains 
and an abnormal haemoglobin ratio (a: non-a). This abnormal ratio leads to 
decreased synthesis of haemoglobin and the expression of thalassaemia. The 
globin that is produced in normal amounts winds up in excess and forms red cell 
aggregates or inclusions. These aggregates become oxidized and damage the 
cell membrane, leading either to haemolysis, ineffective erythropoiesis or both. 
The quantity and properties of these globin chain aggregates determine the 
characteristics and severity of the thalassaemia. 
1.4 Alpha Thalassaemia 
The alpha thalassaemias are caused by a decrease in production of alpha globin 
chains due to a deletion or mutation of one or more of the four alpha globin genes 
located on chromosome 16. Alpha gene mapping can be obtained to determine 
the specific mutation. These are usually due to gene deletions. As there is 
duplication of the a-globin gene, deletion of four genes is needed to completely 
suppress a chain synthesis. (Figure.1.2). 
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The alpha thalassaemias can be generally categorized as: 
i. Silent Carrier 
ii. Alpha Thalassaemia Trait 
iii. Haemoglobin H Disease 
iv. Haemoglobin H-Constant Spring 
v. Alpha Thalassaemia Major. 
Frequently, the diagnosis of alpha thalassaemia trait in parents are discovered 
after the birth of an affected child (Elizabeth George 1998). 
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Figure 1.2: Haemoglobin electrophoretic pattern in normal adult human blood and 
in subject with sickle cell (Hb S) trait or disease, (3-thalassaemia, (3-thalassaemia 
major, Hb S I (3-thalassaemia or Hb S/Hb C disease and Hb H disease 
( A .V .Hoffbrand & J.E.Pettit 1993). 
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1.4.1 Silent Carrier 
The silent carrier status is characterized by three functional genes that code for 
the production of alpha globins (-a/aa). After the newborn period, it is not possible 
to make this diagnosis by conventional methods. There is overlap between the red 
blood cell indices of these individuals and normal, although the MCV may be 
slightly lower. The silent carrier will experience no health problems in his/her 
lifetime. This carrier state is diagnosed by deduction when a 'normal' individual 
has a child with Haemoglobin H disease or with microcytic anemia consistent with 
alpha thalassaemia trait. 
1.4.2 Alpha Thalassaemia Trait 
Alpha thalassaemia trait is characterized by two functional genes that code for the 
production of alpha globins [(-al-a) or (-/aa)]. The two genes can either occur on 
the same chromosome (cis-type) or on each of the pair (trans-type). Cis-type a-
thalassaemia trait tends to be found in individuals of Asian descent, while trans-
type tends to run in individuals of African descent (Emmanuel C. et.al1992). 
Cis-type can be co-inherited with another cis-type or haemoglobin H disease to 
result in alpha thalassaemia major, or hydrops fetalis. Individuals who have alpha 
thalassaemia trait are identified by microcytosis, erythrocytosis, hypochromia, and 
mild anaemia. The diagnosis is made by a combination of family studies and the 
ruling out of both iron deficiency anemia and beta thalassaemia trait. 
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In the neonatal period, when Haemoglobin Bart's (y4) is present, the diagnosis can 
be strongly suspected. In children, there are no markers such as Haemoglobin A2 
and Haemoglobin F to make the diagnosis. (One exception is the case where both 
of the deletions occur on the same chromosome and zeta [~ globin is expressed 
in carriers. This is most common in Southeast Asians ( Wasi P ,et al 1985). The 
diagnosis is by exclusion. The clinician should be satisfied with the presumed 
diagnosis if the above criteria are met. During pregnancy, the microcytic anaemia 
can be mistaken for anemia of pregnancy. The individual with a thalassaemia trait 
will experience no significant health problems accept a possible slight anaemia, 
which cannot be treated with iron. 
1.4.3 Haemoglobin H Disease 
Haemoglobin H disease is characterized by one functional gene that codes for the 
production of alpha globins (-/-a). Haemoglobin H disease should be considered 
in the case of a neonate in whom all of the red blood cells are very hypochromic. 
These neonates have a high percentage of Haemoglobin Bart's on the their 
newborn screening results. In older children, this haemoglobinopathy is 
characterized by moderate anaemia with haemoglobin between 8 to 1 0 gm/dl 
range, hypochromia, microcytosis, red cell fragmentation, and fast migrating 
haemoglobin ( Haemoglobin H) on electrophoresis ( Figure 1.3 ). 
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Haemoglobin H does not function as normal haemoglobin and has a high oxygen 
affinity (holds onto oxygen longer making it unavailable for use by the body}, so 
the measured haemoglobin in these children is misleading. Individuals who have 
Haemoglobin H generally have a persistent stable state of anaemia, which may be 
accentuated by increased haemolysis during viral infections and by exposure to 
oxidant medications, chemicals and foods such as sulfa drugs, benzene and fava 
beans (similar to individuals who have G6PD deficiency}. As the red cells mature 
they loose their ability to withstand oxidant stress and Haemoglobin H precipitates, 
leading to haemolysis. 
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Figure 1.3: Alpha thalassaemia: Haemoglobin H disease (3 a - globin gene 
deletion). The blood film shows marked hypochromic, microcytic cells with target 
cells and poikilocytosis (A.V. Hoffbrand , J .E. Pettit. 1993) _ 
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1.4.4 Haemoglobin Constant Spring 
An unusual case of the silent carrier state is the individual who carries the 
Haemoglobin Constant Spring mutation. This is an elongated a-globin due to a 
termination codon mutation. Individuals who have this mutation have normal red 
blood cell indices, but can have children who have Haemoglobin H-constant 
spring disease if the other parent has alpha thalassaemia trait ( -/aa). 
Generally, children with Haemoglobin H-Constant Spring are more affected 
clinically than children who have classic Haemoglobin H disease. Two constant 
spring carriers can also pass on their genes to have a child with homozygous 
constant spring, a condition that has similar clinical implications as Haemoglobin H 
disease. Children with Haemoglobin Constant Spring (-/aa) have a more severe 
course than children who have Haemoglobin H. They have a more severe 
anaemia, with steady state haemoglobin ranging between 7 and 8 gm/dl. 
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1.4.5 Alpha Thalassaemia Major 
The most severe form of alpha thalassaemia is a.-thalassaemia major or hydrops 
fetalis, characterized by a deletion of all four genes that code for alpha globins 
(-/-). This diagnosis is frequently made in the last months of pregnancy when 
fetal ultrasound indicates a hydropic fetus. The mother frequently exhibits toxemia 
and can develop severe postpartum haemorrhage. These infants are usually 
stillborn. 
There can be other congenital anomalies, though none are pathognomonic for a.-
thalassaemia major. Since a- glob ins are required for production of fetal and adult 
haemoglobin, the fetus suffers from significant in hypoxia uterus. The only 
haemoglobins found in these infants are: Haemoglobin Portland (o2y2"), 
Haemoglobin H (J34), and Haemoglobin Bart's (y4), and no Haemoglobin A or A2. 
These babies can have other complications associated with hydrops, such as 
heart failure and pulmonary edema. 
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1.5 Beta Thalassaemia 
There are hundreds of mutations within the beta globin gene, but approximately 
20 different alleles comprise 80% of the mutations found worldwide. Within each 
geographic population there are unique mutations. Individuals who have beta 
thalassaemia major are usually homozygous for one of the common mutations, or 
heterozygous for one of the common mutations and one of the geographically 
unique mutations. Both lead to absence of beta globin chain production. 
The beta thalassaemia syndromes are much more diverse than the alpha 
thalassemia syndromes due to the diversity of the mutations that produce the 
defects in the beta globin gene. Unlike the deletions that constitute most of the 
alpha thalassaemia syndromes, beta thalassaemias are caused by mutations on 
chromosome 11 that affect all aspects of beta globin production: transcription, 
translation and the stability of the beta globin product. Most haematologists feel 
there are three general categories beta thalassaemia : 
i. Beta thalassaemia trait (p+/pA,po/pA) 
ii. Beta thalassaemia intermedia (p+/p+,p+/p~ 
iii. Beta thalassaemia major (f3°/f3~ 
17 
Splice site mutations also occur and are of clinical consequence, when combined 
with a thalassaemia mutation. Three splice site mutations occur in exon 1 of the 
beta globin gene. (Figure 1.4). 
These mutations result in three different abnormal haemoglobins: 
i. Hb Malay 
ii. Hb E 
iii. Hb Knossos 
Haemoglobin E is very common abnormal haemoglobin in the Southeast Asian 
population, and when paired with a (3° thalassaemia mutation, can produce severe 
transfusion-dependent (EJ3<) thalassaemia (Elizabeth George.1998). 
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Figure 1.4: Distribution of different mutations of 13-thalassaemia major round the 
Mediterranean (A.V. Hoffbrand, J.E. Pettit. 1993) . 
19 
1.5.1 Beta Thalassaemia Trait 
Individuals who have beta thalassaemia trait have microcytosis and hypochromia 
, target cell and elliptocytosis. Some individuals have an almost normal smear. 
Blood indices usually low MCV and MCH but red cell count high. The 
heterozygous state for f3+ or f3°-thalassaemia result in f3- thalassaemia trait. 
Haemoglobin usually 1 0-15g/dl. Haemoglobins A2 and F will be elevated on 
haemogram results. 
These haematologic features can be accentuated in women with trait who are 
pregnant and in individuals who are folate or iron deficient. In iron, 8 12 and folate 
replete individuals, the Haemoglobin A2 can be as high as 3.5 to 8% and the 
Haemoglobin F as high as 1 to 5%. Generally, beta thalassaemia trait is milder in 
African-Americans (who frequently have a promoter gene mutation) but has a 
similar presentation in individuals of Chinese, Southeast Asian, Greek, Italian and 
Middle Eastern heritage. (D.J. Weatherall and J.B.Ciegg. 2001). 
20 
1.5.2 Beta Thalassaemia lntermedia 
Children who are diagnosed with thalassaemia intermedia have a homozygous or 
heterozygous 13-globin mutation that causes a decrease in 13-chain production, but 
not to the degree that chronic transfusion therapy is required. The phenotype can 
also occur in children who have a mutation that increases production of J3-globin, 
in children who have co-inherited alpha thalassaemia and beta thalassaemia and 
in other rare mutations. 
Children who have thalassaemia intermedia are able to maintain a haemoglobin of 
7 gm/dl or slightly higher with a greatly expanded erythron and may manifest bony 
deformities, pathologic fractures and growth retardation. The homozygous state 
for J3+-thalassaemia (f3+/f3} and the compound heterozygous state ((3+ I f3j result in 
thalassaemia intermedia. 
Children who cannot maintain haemoglobin between 6 and 7 gm/dl should have 
an alternative diagnosis considered. If thalassaemia is the cause of the anaemia, 
transfusion and/or splenectomy should be considered (Elizabeth George.1998). 
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1.5.3 Beta Thalassaemia Major 
Beta thalassaemia major is the most severe form of beta-thalassaemia. Present 
management consists of regular monthly blood transfusions designed to maintain 
the mean haemoglobin level of 1 0-11 gm/dl. The iron derived from the transfused 
red blood cells, and to a lesser extent from increased gut absorption of iron 
because of ineffective erythropoiesis accumulates in several parenchyma organs. 
Beta thalassaemia major also occur in children who have a mutation that 
decreased production of J3-globin, in children who have co-inherited a-thalassaemia 
and (3-thalassaemia and in other rare mutations. The homozygous state for f3° 
((3°/(3~ causes a severe transfusion dependent anaemia termed thalassaemia 
major. There is a severe hypochromic microcytic anaemia with raised reticulocyte 
percentage with normoblasts, target cells and basophilic stippling in the blood 
(A.V. Hoffbrand, J.E. Pettit. 1983). 
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1.6 Thalassaemia Haemoglobinopathies 
Thalassaemia haemoglobinopathies are structural abnormalities of haemoglobin 
synthesis, where the synthesis of these haemoglobin's are reduced in amount. 
The thalassaemia is caused by abnormal processing of mRNA or as a result of 
instability of the abnormal globin chain ( Elizabeth George.1998). 
Common thalassaemia haemoglobinopathies in Malaysia are: 
Hb E 
ii Hb Malay 
iii Hb New York 
iv Hb Constant Spring 
1.6.1 Variant Haemoglobin's 
Haemoglobin E is very common among Southeast Asians, California Newborn 
Screening Program found that 1 in 12 Southeast Asians, and 1 in 4 Cambodian 
newborns had Hb E trait. Hb EE (homozygous) has not been shown to have 
serious medical implications. Haemoglobin E-Beta thalassaemia has a wide range 
of clinical manifestations, from mild anemia to significant anemia requiring chronic 
transfusions (Cao A, Rosatelli MC. 1993). 
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1.7 General Guideline for Donor 
To give blood for transfusion to another person, a donor must be healthy, be at 
least 17 years old, weight at least 11 0 pounds and have not donated blood in the 
last 56 days. ..Healthy .. means that feeling well and can perform normal activities. 
Other aspects of each potential donor's health history are discussed as part of the 
donation process before any blood is collected. 
Each donor receives a brief examination during which temperature, pulse, blood 
pressure and blood count (haemoglobin or haematocrit) are measured. Making 
donations for your own use during surgery (autologous blood donation) is 
considered a medical procedure and the rules for eligibility are less strict than for 
regular volunteer donations.( R.A.R., MD and M.A.P., RN,BSN the American red 
cross). 
1. 7.1 Who should not donate blood? 
Anyone who has ever used intravenous drugs (illegal IV drugs). 
ii Men who have had sexual contact with other men since 1977. 
iii Haemophiliacs. 
iv Anyone with a positive antibody test for HIV (AIDS virus). 
v Men and women who have engaged in sex for money or drugs since 
1977. 
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